Takeda reports FY2026 H1 results, launches ORZEYFUL and MIMRYLO, upgrades FY outlook
Takeda Pharmaceutical announced its FY2026 first‑half results, highlighting U.S., Japan and China approvals of ORZEYFUL for narcolepsy type 1 and the U.S. launch of MIMRYLO for polycythemia vera. The company also disclosed that the FDA has placed zasocitinib under Priority Review for plaque psoriasis. On the financial side, revenue rose 8.4% on an actual‑exchange‑rate basis and core operating profit was forecast to reach ¥1.19 trillion for the full year, reflecting foreign‑exchange benefits.
Why it matters
The upgraded full‑year core operating profit guidance, announced by Takeda’s CEO, signals higher expected earnings for FY2026, which may lift the stock’s valuation. The new product launches add near‑term revenue streams and diversify the pipeline, potentially improving future cash flow.
Key facts
- 1ORZEYFUL was approved in the United States, Japan and China for narcolepsy type 1. brantfordexpositor.ca
- 2MIMRYLO launched in the United States in August 2026 for polycythemia vera. brantfordexpositor.ca
- 3The FDA accepted the new‑drug application for zasocitinib under Priority Review. brantfordexpositor.ca
- 4Revenue increased 8.4% versus the prior period on an actual‑exchange‑rate (AER) basis. brantfordexpositor.ca
- 5Core operating profit guidance for FY2026 was raised to ¥1.19 trillion. seekingalpha.com
- 6Core EPS for the first half was 308 JPY, up 10.5% on an AER basis. brantfordexpositor.ca
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.